Sacramento LGBT Center loses $500K in federal funds for mental health services
The federal Department of Health and Human Services suddenly canceled more than billions of dollars in federal grants from the Centers for Disease Control and Mental Health Services Administration to states for mental health, recovery support, HIV, and other infectious diseases prevention.
According to the Sacramento LGBT Community Center, the result of this action has caused an immediate termination of a mental health grant to the center with nearly $500,000 remaining on their contracts. As a result, the center is now calling for community support and for the government to take action on this.
'This decision leaves some of the most vulnerable members of our community without access to critical services,' said David Heitstuman, CEO. 'We are working around the clock to preserve continuity of care and ensure clients aren't showing up for their counseling appointments with no one to see them, but we cannot do it alone.'
Priya Kumar, Communications and Marketing Manager for Sacramento LGBT Community Center stated the center serves hundreds of LGBTQ+ individuals every year under the program, which includes unhoused youth, people living with substance use disorder, and those navigating mental health crises.
The center was notified on April 1 that all funding ceased as of March 24 with no warning and no phase-out period, stated Kumar in a news release. The termination not only has affected the Sacramento region but also communities across California and the United States.
'We are still seeking clarification from the federal government as to the specific reasons for this lapse in communication,' said Kumar. 'The lack of timely notification created a situation where the Center had to retroactively adjust to the loss of funding.'
Kumar stated the center is looking for emergency funding, public support, and legislative advocacy to continue serving those whose care is at risk. Kumar says the one-week delay has caused many disruptions to their services.
'This has created a very difficult situation for our clients & community,' said Kumar.
Kumar told FOX40.com that now their priority is to mitigate the damage and continue to provide essential services to our community and still advocate for greater transparency when it comes to future funding decisions.
LGBTQ+ youths face mental health emergencies that are heightened by hostile legislation, social stigma, and identity-based discrimination, stated Kumar.
To highlight the work done by the center, Kumar points to The Trevor Project's 2024 U.S. National Survey on the Mental Health of LGBTQ+ Young People. According to that survey:
39% of LGBTQ+ youth seriously considered suicide in the past year
Among transgender and nonbinary youth, the rate jumps to 46%
50% of LGBTQ+ youth who sought mental health care were unable to access it
LGBTQ+ youth in affirming environments — have significantly lower suicide risk
If you would like to donate to the center you can click here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
2 hours ago
- Time Business News
Next-Gen Breakthroughs Reshaping the In Vitro Diagnostics
In vitro diagnostics (IVD) refers to tests on blood, tissue, or other samples taken from the human body to detect diseases, conditions, or infections. These tests are usually used in laboratories or at the point of care for diagnosis, monitoring and treatment guidance. IVD market has increased due to increased chronic and infectious diseases, increasing demand for early and accurate diagnosis, progress in clinical technologies (eg molecular diagnosis and AI-operated equipment), expansion of elderly population, and globally more healthcare awareness. Key Growth Drivers and Opportunities Increased Chronic and Infectious Diseases: An increase in chronic and infectious diseases increases in vitro diagnostics (IVD) market, as these conditions require initial, accurate and continuous testing for effective treatment and management. Chronic diseases such as diabetes, cancer, and heart disease demand regular monitoring through blood tests, biomarkers and genetic screening, while infectious diseases such as Covid -19, HIV and tuberculosis increase the need for rapid and large -scale clinical solutions. This increased disease burden increases the demand for advanced IVD tools, which is motivated to adopt health care systems more efficient, automatic and accurate clinical technologies to improve the results of the patient. Challenges In vitro diagnostics (IVD) market faces several borders, including high costs, regulatory complications, and reimbursement challenges of advanced clinical technologies that obstruct market access. Limited infrastructure and skilled workers also prohibit adoption in low- and moderate-income countries. Additionally, concerns over the accuracy and standardization of some rapid or point-key-care tests can affect confidence in reliability and results, slowing out extensive implementation. Innovation and Expansion Launch of a New HealthTech Hub to Promote In Vitro Diagnostics In March 2025, Industry, academia, and the healthcare sector convened at the NIHR HealthTech Research Centre in In Vitro Diagnostics (HRC IVD) opening event to deliberate on the Center's goals and priorities. The HRC IVD, which is hosted by Imperial College London and Imperial College Healthcare NHS Trust and funded by the National Institute for Health and Care Research (NIHR), will aid in the advancement and uptake of diagnostics. The HRC IVD provides experience in regulatory clearances, real-world evidence creation, health economics, and overcoming adoption hurdles, with a focus on cancer, infectious and respiratory illnesses, critical care, and primary and social care. MP Biomedicals Releases Next-Generation GI Disease Diagnostic Kits In August 2024, MP Biomedicals has added new qualitative fast tests based on immunochromatography to their suite of in vitro diagnostic assays for infectious disorders. The new diagnostic kits from MP Biomedicals use state-of-the-art technology to provide reliable findings, allowing medical practitioners to quickly and accurately detect Vibrio cholerae serogroups O1 and O139, Salmonella typhi, and Helicobacter pylori. These cutting-edge diagnostic technologies have the potential to completely transform the field of gastrointestinal health diagnostics by giving medical practitioners dependable instruments for enhanced patient outcomes and early identification with previously unheard-of precision. These kits provide doctors, lab workers, and researchers useful tools that may be used in both clinical and research contexts. Inventive Sparks, Expanding Markets The key players operating the in vitro diagnostics market includes, Abbott, Qiagen, Agilent Technologies Inc., bioMerieux SA, Siemens Healthineers, Sysmex Corp., Danaher Corporation, F-Hoffman-La Roche Ltd., Charles River Laboratories, Becton Dickinson and Company, and Others. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
Yahoo
3 hours ago
- Yahoo
Infectious Disease Therapies Market Projected to Reach $101 Billion by End of 2030
"As infectious diseases like HIV, hepatitis, tuberculosis, and influenza continue to challenge global health systems, new breakthroughs such as long acting injectables and monoclonal antibodies are driving better patient outcomes and fueling market growth, especially in the face of rising drug resistance." BOSTON, Aug. 14, 2025 /PRNewswire/ -- According to the latest study from BCC Research, "Global Markets for Infectious Disease Treatments" is expected to grow from $72.5 billion in 2025 to $101 billion by the end of 2030, at a compound annual growth rate (CAGR) of 6.9% during the forecast period of 2025 to 2030. This report analyzes the global market for infectious disease therapeutics, vaccines, and diagnostics, covering diseases such as HIV, influenza, hepatitis B and C, RSV, TB, HSV, malaria, rotavirus, and viral hemorrhagic fevers. It highlights market trends, challenges, and opportunities, along with insights into new products, acquisitions, collaborations, and ESG developments. The report also ranks leading companies by market share and provides detailed profiles of them. Excluded from the report are vector control strategies, symptomatic treatments, generic suppliers, and certain hospital-based diagnostic methods. This report is particularly relevant today because the COVID-19 pandemic has reshaped global priorities around infectious diseases. It exposed critical gaps in healthcare systems and underscored the urgent need for rapid diagnostics, effective treatments, and scalable vaccine platforms. In response, governments, organizations, and private companies invested in infectious disease research and infrastructure, driving innovation and global collaboration. The pandemic also highlighted the importance of early detection, surveillance, and preparedness, leading to renewed attention on emerging and neglected infectious diseases. The factors driving the market's growth include: Increasing Resistance to Drugs: Drug resistance is rising as bacteria and viruses evolve to withstand existing treatments, making infections harder to cure. This pushes pharmaceutical companies to develop new drugs and therapies, driving growth in the infectious disease treatment market. Global Efforts to Combat Infectious Diseases: Governments and international organizations are investing in public health initiatives, research, and vaccination programs to control infectious diseases. These efforts create strong support for treatment development and expand market opportunities worldwide. Technological Advances in Diagnostics and Therapeutics: Innovations like rapid testing, AI-based drug discovery, and advanced vaccines are improving how diseases are detected and treated. These technologies enhance efficiency and effectiveness, boosting demand for more effective diagnostic and therapeutic solutions. Climate Change: Changing climate patterns are expanding the reach of disease-carrying organisms, leading to the spread of infections in new regions. This increases the need for treatments in previously unaffected areas, stimulating market expansion and adaptation. Request a sample copy of the global market for infectious disease treatments report. Report Synopsis Report Metric Details Base year considered 2024 Forecast period considered 2025-2030 Base year market size $68.3 billion Market size forecast $101 billion Growth rate CAGR of 6.9% for the forecast period of 2025-2030 Segments covered Product, Disease, and Region Regions covered North America, Europe, Asia-Pacific, Middle East and Africa, and South America Countries covered U.S., Canada, Mexico, U.K., Germany, France, China, India, and Japan Market drivers • Increasing resistance to drugs. • Global efforts to combat infectious diseases. • Technological advances in diagnostics and therapeutics. • Climate change. • Increase in international travel. Interesting facts: More than 85% of hepatitis B virus infections never receive a diagnosis. Due to climate change, mosquito-borne infectious diseases are on the rise. The worldwide incidence of dengue has risen eightfold in the past 20 years. Emerging startups: Codagenix: The company develops vaccines and viral therapeutic candidates for infectious diseases. Its intranasal vaccine candidate, CoviLiv, is a live-attenuated vaccine against COVID-19. nChroma Bio: A biotechnology company advancing genetic medicines. CRMA-1001 is an epigenetic editor in development as a potential treatment for chronic hepatitis B and hepatitis D. The company plans to submit a clinical trial application in 2025. The report addresses the following questions: What are the projected size and growth rate of the Infectious disease treatments market?- The global Infectious disease treatments market was estimated at $68.3 billion in 2024. The market is projected to reach $101 billion in 2030, growing at a CAGR of 6.9% during the forecast period. Which market segments are covered in the report?- The report includes historical data and market projection on sales by product type, disease, and region. Which product type segment will be dominant through 2030?- Therapeutics is expected to have the largest share of the product type segment through the end of 2030. Which product type is showing the fastest growth?- The vaccine segment is the fastest growing product type segment. What are the key challenges and opportunities in the market?- Challenges: Pricing pressure is a significant factor restraining the growth of the infectious disease treatment market, particularly in low and middle-income countries where healthcare budgets are limited. Lack of awareness and underdiagnosis remain major barriers to the growth of the infectious disease treatment market.- Opportunities: Self-testing kits are rapidly gaining traction in the field of infectious diseases, offering individuals convenient, private, and timely diagnostic options. Market leaders include: ABBOTT ABBVIE INC. CSL DANAHER CORP. F. HOFFMANN-LA ROCHE LTD. GILEAD SCIENCES INC. GSK PLC JOHNSON & JOHNSON MERCK & CO. INC. MOLBIO DIAGNOSTICS LTD. ORASURE TECHNOLOGIES INC. PFIZER INC. SANOFI SERUM INSTITUTE OF INDIA PVT. LTD. SIEMENS HEALTHINEERS Related reports: The Global Influenza Market: This report provides a comprehensive review of the global influenza market, offering qualitative and quantitative insights. It explores the historical context of flu pandemics, current disease burden, and vaccine coverage across key regions. The market is segmented into vaccines (inactivated and live-attenuated), therapeutics, and diagnostics (rapid and conventional tests), with detailed analysis of each category. It also highlights leading products, clinical trials, new approvals, and emerging technologies. Regional demographics and growth prospects in North America, Europe, and Asia-Pacific are examined, along with strategic profiles of major companies operating in the influenza sector. Purchase a copy of the report direct from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact Us Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA Email: info@ Phone: +1 781-489-7301 For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo - View original content to download multimedia: SOURCE BCC Research LLC Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
a day ago
- Medscape
Pediatric-to-Adult HIV Transition Model Shows Mixed Results
TOPLINE: The Adolescent and Young Adult (AYA) Healthcare Transition (HCT) clinic — a pediatric-to-adult HIV care model — achieved a high 1-year retention rate but a suboptimal viral suppression rate despite high engagement in care. Ryan White funding and program adaptability emerged as key strengths, while the region's political climate and HIV stigma remained as major barriers. METHODOLOGY: AYAs with HIV infection transitioning to adult care face challenges such as low retention and poor viral suppression; AYAHCT clinic was designed to address these issues and improve health outcomes in this population. Researchers conducted a mixed-methods analysis to evaluate the design, implementation, and early clinical outcomes of the AYAHCT clinic set up within the Adolescent and Young Adult Health Clinic in the Southeastern US. Quantitative analysis included 18 patients with HIV infection (mean age at first visit, 19.8 years; 78% boys) retrospectively assessed for clinical outcomes including clinic visit attendance, viral suppression, and retention in care. Qualitative analysis included nine semistructured interviews with key stakeholders in pediatric, AYAHCT, and adult HIV clinics to address facilitators of and barriers to clinic implementation. TAKEAWAY: Patients in the AYAHCT clinic averaged 4.4 visits per year, achieved 100% retention in care after 1 year, and had a viral suppression rate of 79.3%. Among the seven patients who transitioned from the AYAHCT clinic to adult care, retention remained high at 85.7%, with viral suppression improved to 96.8%. Key facilitators of clinic implementation included Ryan White funding, strong community connections, positive attitudes among providers and staff, and program adaptability. Major barriers were HIV-related stigma, the region's political climate, clinic workflow challenges, and adverse social determinants of health. IN PRACTICE: 'Our study described an innovative care model to improve AYA retention in HIV care, with future opportunities to improve VL [viral load] suppression,' the authors wrote. SOURCE: This study was led by Nina E. Hill, University of Michigan, Ann Arbor, Michigan. It was published online on July 21, 2025, in AIDS Care. LIMITATIONS: This study was limited by its small sample size, affecting the generalizability of the findings. The HIV care model involving both adolescent medicine and HIV specialists may not have been applicable to all settings. Long-term follow-up after transition to the adult HIV clinic was limited. DISCLOSURES: This study was supported by the Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center. The authors reported having no potential conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
